Munich, Germany, April 30, 2012 — Definiens®, the leading provider of image analysis and data mining solutions for quantitative digital pathology, announced today it has been selected as a Finalist for Red Herring’s Top 100 Europe award, a prestigious list honoring the year’s most promising private technology ventures from the European business region.
Attend the upcoming webinars in our “Quantitative Digital Pathology Made Easy” series. This Thursday, Mark Lloyd from the Moffitt Cancer Center will present his exciting research into how single-cell features elucidate spatially heterogeneous morphotypes in histological tissue sections. Next week, Martin Baatz from Definiens will emphasize that automated image analysis yields substantial productivity gains for pre-clinical safety studies.
We would be delighted to welcome you on the webinars and to answer your questions.
Best regards,
The Definiens team
Single-Cell Features Elucidate Spatially Heterogeneous Morphotypes in Histological Tissue Sections
(Mark Lloyd, Moffitt Cancer Center, April 26, 11am EDT/8am PST/5pm CEST)
Automated Image Analysis in Pre-clinical Safety Studies: Increasing Productivity and Delivering Significant Return on Investment
(Martin Baatz, May 2, 11am EDT/8am PST/5pm CEST)
Visit http://info.definiens.com/01QuantitiatveDigitalPathologyOutoftheBox_WebinarPage.html to register.
Program features latest trends in quantitative digital pathology and tissue-based biomarker development with leading experts from Roche, AstraZeneca, Novartis and cutting-edge biomedical image and data analysis during hands-on workshops
Munich, Germany, April 19, 2012 — Definiens®, the global leader of image and data analysis solutions for quantitative digital pathology, invites professionals interested in pathology and biomarker development to the 3rd International Definiens Symposium. The symposium will be held at the Definiens headquarters in Munich from June 14-16, 2012.
The annual event is the premier forum for the latest trends in quantitative research in histology, tissue-based biomarker development and cutting-edge biomedical image and data analysis. It brings together experts from around the world to share best practices and experiences. This year’s keynote lecture will be delivered by Dr. Frauke Bentzien from Exelixis, one of the pioneers in quantitative digital pathology who has been successfully applying this new paradigm in preclinical safety studies and clinical trials for many years.
The Definiens Symposium offers attendees the opportunity to network with peers and renowned experts and learn from their approaches and experiences. A one-day pre-conference workshop will provide hands-on experiences and training on the latest Definiens solutions for image analysis and data mining.
Nobel Laureate Prof. Gerd Binnig, Founder and CTO Definiens, will share his vision for the next generation of pathology tools, while leading experts from Roche, AstraZeneca, Novartis, GlaxoSmithKline and Johnson & Johnson, as well as practitioners from other renowned institutions, will contribute insights from their work. To find the full speaker panel and the workshop program, visit http://www.definiens.com/community/symposium.html.
“We are delighted to have such a distinguished group of speakers,” stated Thomas Heydler, CEO of Definiens. “The digital pathology market is quickly transitioning into a second phase of adoption where quantitative approaches allow us to unveil the real value of digital slides and are currently transforming pathology into a quantitative discipline. By bringing together thought leaders, experts and users, the International Definiens Symposium provides a very stimulating forum for learning about the future of this exciting field.”
Previous International Definiens Symposia were held at the Spanish Cardiovascular Research Center in Madrid in 2010 and the Moffitt Cancer Center in Tampa, FL in 2011. The symposia received excellent feedback from participants. “I thought the conference was outstanding! The quality of the speakers and the visionary spirit combined with the demonstration of exciting achievements at the forefront of quantitative pathology were very inspiring,” said Prof. Manfred Dietel from the Institute of Pathology at the Charité Berlin.
Susan Young wrote a post on technology review on a lecture held last Thursday at the 2012 TEDMED conference by Otis Brawley, Chief Medical Officer of the American Cancer Society. Here’s an interesting passage (click here to read the full article):
“Pathologists still use drawings made in 1840 to determine whether the cells in a biopsy are cancerous or not, said Brawley. When a lump is deemed to be cancerous, surgery often follows. But as many as 25% of breast cancers and, by some estimates, 60% of prostate cancers could be left untreated and merely monitored, he said.
Brawley said the medical community needs to use genomic sequencing to identify the genetic signals of those cancers that doctors need to watch and those that need to be treated. This could be achieved by sequencing tumors from different cancer patients and looking for a genetic “profile” that is associated with dangerous, stable, or benign cancers.”
While it seems like a good idea to go beyond drawings made in 1840 it remains to be seen if genomic sequencing alone will do much better. Tumors have been looked at to evaluate whether they are dangerous, stable or benign because tissue morphology contains very relevant information.
The annual event is the premier forum for anyone interested in latest trends in Quantitative Digital Pathology, tissue-based biomarker development and cutting-edge biomedical image and data analysis with Definiens.
Register now to secure early bird registration fee. Regular registration will be open until May 15.
Visit http://www.definiens.com/community/symposium.html to learn more or click here to see recordings of presentations held at the 2011 event at the Moffitt Cancer Center.
Keith Kaplan recommends an interesting book on the digital pathology blog. Click here to read his post or see below.
Last month ASCP Press published a new book on pathology informatics, the first multi-authored textbook on the subject geared towards a comprehensive review of the field of pathology informatics. Drs. Pantanowitz (UPMC), Weinstein (U of Arizona) and myself have a chapter devoted to telepathology and whole slide imaging. A must read (at a great price) for resident or practicing pathologist alike as well as anyone with interests in the diverse nature of pathology informatics for practical management, operations, budgeting and project planning.
